Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
360
Trial Sponsor
Clinical Trial Start Date
June 7, 2024
0Primary Completion Date
September 30, 2025
0Study Completion Date
September 30, 2025
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Phase 20
Official Name
A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension0
Last Updated
May 21, 2024
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Investigator0
Care Provider0
Participant0
Other attributes
Intervention Treatment
Placebo0
Zilebesiran0
Study summary
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
